Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abgenix Run-Up In Value Ends Cell Genesys/Genzyme Merger

Executive Summary

Cell Genesys spin-off Abgenix' success in marketing its XenoMouse technology has helped terminate a proposed merger between Genzyme and Cell Genesys.
Advertisement

Related Content

The XenoMouse That Roared: Cell Genesys' Share Of Abgenix Worth $781 Mil.
The XenoMouse That Roared: Cell Genesys' Share Of Abgenix Worth $781 Mil.
Amgen Is Biotech Again; Genomic Data Drives Sector To New Highs
Amgen Is Biotech Again; Genomic Data Drives Sector To New Highs
Advertisement
UsernamePublicRestriction

Register

PS035355

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel